Company intelligence / Profile preview

XCath

Houston, Texas, United States

Ownership: Private
Employees: ~90
Development stage: Other

Overview

XCath has demonstrated a first-in-kind live telerobotic mechanical thrombectomy trial between Abu Dhabi and South Korea, showing the potential of their robotic platform for remote stroke intervention and expanding treatment options for acute neurovascular conditions. Their technology has not yet achieved full commercial approval, but pivotal clinical validation is underway, including first-in-human trials planned imminently.

Therapeutic areas: Neurology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Collaboration with clinical sites and expert physicians (multiple international clinical collaborations)Device integration testing collaborations (e.g., Stryker neurovascular devices during demonstration)

Beyond the preview

Go deeper on XCath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XCath.

Explore the full profile